AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03712007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAMP therapy with MARPE expander
Description: Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
Study NCT03712007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAMP therapy with Hyrax expander
Description: Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
Study NCT03458715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (Empagliflozin 25 MG)
Description: We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
Study NCT03458715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP4 inhibitor (Linagliptin 5 MG)
Description: We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
Study NCT03679442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
Study NCT01564056 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HORMONOTHERAPY
Description: Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Study NCT02964260 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy drug
Description: Doxorubicin/Platinum agents
Study NCT02964260 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Embolic agents
Description: Lipiodol/Gelatin sponge/PVA/Blank microspheres
Study NCT02964260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Embolic agents
Description: Lipiodol/Gelatin sponge/PVA/Blank microspheres
Study NCT02964260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneously
Description: 1-3 days
Study NCT02964260 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sequentially
Description: 1 month
Study NCT02964260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation
Description: Radiofrequency ablation/Microwave ablation
Study NCT02964260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Radiofrequency ablation/Microwave ablation
Study NCT02360982 — intervention group
Intervention type: BEHAVIORAL
Intervention: propofol and esmeron(rokuronyum)
Description: All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
Study NCT03856944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR Toric
Description: ReSTOR Toric bilateral IOL implantation
Study NCT04547322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR application group
Description: During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
Study NCT01564056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHEMOTHERAPY then HORMONOTHERAPY
Description: CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Study NCT02446171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
Study NCT02446171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
Study NCT02360982 — intervention group
Intervention type: BEHAVIORAL
Intervention: marcaine and fentanyl
Description: All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
Study NCT04641130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to birch pollen in EEC
Description: Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
Study NCT00707161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
Study NCT00707161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
Study NCT02446171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg (10 mL oral solution)
Description: naloxegol 25 mg (10 mL oral solution)
Study NCT00707161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
Study NCT02446171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg tablet, given orally
Description: naloxegol 25 mg (1 tablet) whole tablet, given orally
Study NCT03712423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cripec Docetaxel
Description: 89 Zirconium Cripec Docetaxel PET
Study NCT02648633 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Subjects will receive a single large dose of radiation to one or more lesions.
Study NCT02648633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
Study NCT02648633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
Study NCT00669409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 10 mcg/kg IV
Study NCT03543462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: thoracic Drain Tube 24 Fr.
Description: Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
Study NCT01406418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 2 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study NCT00669409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 100 mcg/kg IV
Study NCT00669409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 200 mcg/kg IV
Study NCT00669409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 25 mcg/kg IV
Study NCT00669409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119 (tanezumab)
Description: single dose of 50 mcg/kg IV
Study NCT00669409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-04383119 (tanezumab)
Description: single dose of Placebo IV
Study NCT02879045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elasticity Belly® oil
Description: We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
Study NCT03502330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
Study NCT02984072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: Topical menthol in aqueous cream
Study NCT02984072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous Cream
Description: placebo
Study NCT01324518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: 60mg twice a day
Study NCT01324518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: 200mg twice a day
Study NCT01324518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ORM-12741
Description: Placebo twice a day
Study NCT02645838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: 1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
Study NCT02578719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: marcaine %0.5 20 ml flacon
Study NCT02578719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: %0.9 sodium chloride
Study NCT03733990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-1305 (bexmarilimab)
Description: The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Study NCT02654964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Drug Therapy
Description: Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent
Study NCT03885167 — intervention group
Intervention type: OTHER
Intervention: Specimen Collection
Description: No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
Study NCT02168387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous high frequency oscillator (CHFO)
Study NCT02168387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Study NCT02168387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa
Study NCT03502330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
Study NCT03502330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
Study NCT02265484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose+Rifaximin +Bromocriptine
Study NCT02265484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose+Rifaximin +Bromocriptine
Study NCT01029730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
Study NCT01029730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
Study NCT01029730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
Study NCT03757884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness breathing exercise
Description: Spire monitor instructed mindfulness breathing
Study NCT03757884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic Checklist
Description: Checklist reminder for diagnosis
Study NCT03757884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise cancelling headphones
Description: Noise cancelling headphones
Study NCT03757884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Privacy tablescreen
Description: Privacy Tablescreen
Study NCT03757884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic assistance application
Description: Diagnostic assistance application
Study NCT03339492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RCStim Model 1114
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal
Study NCT03339492 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RCStim Model 1114
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal
Study NCT01873755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asthma physical activity intervention
Description: School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
Study NCT02626676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Programme
Description: Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
Study NCT02653950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Description: Endoscopic surgery; septoplasty with or without middle turbenectomy
Study NCT02653950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional septoplasty
Description: septoplasty under direct vision
Study NCT00352703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kepivance (Palifermin)
Study NCT03228121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment Then Placebo
Description: Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
Study NCT03228121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo Then Treatment
Description: Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
Study NCT04006184 — intervention group
Intervention type: OTHER
Intervention: Chart review
Description: Retrospective review of medical records at a single site with six physicians
Study NCT02103140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility-based Exercise
Description: Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
Study NCT02103140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
Study NCT01344967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
Study NCT01341457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously
Study NCT01341457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study NCT01823809 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: adenosine stress Cardiac Magnetic Resonance Imaging
Study NCT00365989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Enhanced Sonication
Study NCT01676831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical resiquimod 0.06%
Description: topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
Study NCT04424329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibers and probiotics
Description: A blend of fibers and seven probiotics
Study NCT01046435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metronidazole and amoxicillin
Description: Metronidazole 250 mg three times a day per 7 days
Study NCT01046435 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: metronidazole and amoxicillin
Description: Metronidazole 250 mg three times a day per 7 days
Study NCT01046435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two placebos
Description: Two placebos 3 times a day for 7 days
Study NCT01046435 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Two placebos
Description: Two placebos 3 times a day for 7 days
Study NCT05099224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: similar to the information included in arm/group descriptions
Study NCT01222156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation
Description: Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias